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Abstract
Background: Genomic medicine has paved the way for identifying biomarkers and therapeutically actionable
targets for complex diseases, but is complicated by the involvement of thousands of variably expressed genes
across multiple cell types. Single-cell RNA-sequencing study (scRNA-seq) allows the characterization of such
complex changes in whole organs.
Methods: The study is based on applying network tools to organize and analyze scRNA-seq data from a mouse
model of arthritis and human rheumatoid arthritis, in order to find diagnostic biomarkers and therapeutic targets.
Diagnostic validation studies were performed using expression profiling data and potential protein biomarkers from
prospective clinical studies of 13 diseases. A candidate drug was examined by a treatment study of a mouse model
of arthritis, using phenotypic, immunohistochemical, and cellular analyses as read-outs.
Results: We performed the first systematic analysis of pathways, potential biomarkers, and drug targets in scRNA-
seq data from a complex disease, starting with inflamed joints and lymph nodes from a mouse model of arthritis.
We found the involvement of hundreds of pathways, biomarkers, and drug targets that differed greatly between
cell types. Analyses of scRNA-seq and GWAS data from human rheumatoid arthritis (RA) supported a similar
dispersion of pathogenic mechanisms in different cell types. Thus, systems-level approaches to prioritize biomarkers
and drugs are needed. Here, we present a prioritization strategy that is based on constructing network models of
disease-associated cell types and interactions using scRNA-seq data from our mouse model of arthritis, as well as
human RA, which we term multicellular disease models (MCDMs). We find that the network centrality of MCDM cell
types correlates with the enrichment of genes harboring genetic variants associated with RA and thus could
potentially be used to prioritize cell types and genes for diagnostics and therapeutics. We validated this hypothesis
in a large-scale study of patients with 13 different autoimmune, allergic, infectious, malignant, endocrine, metabolic,
and cardiovascular diseases, as well as a therapeutic study of the mouse arthritis model.
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Conclusions: Overall, our results support that our strategy has the potential to help prioritize diagnostic and
therapeutic targets in human disease.
Keywords: Network tools, scRNA-seq, Biomarker and drug discovery,
Background
One of the most important problems in health care
today is that many patients do not respond to drug
treatment. According to an FDA report, this affects 38–
75% of patients with common diseases [1]. This problem
is closely linked to increasing costs and difficulties in
drug development [2]. One important driver of this high
rate of failure is suggested by genome-wide association
studies (GWAS), which identify increasing numbers of
genetic variants that may affect highly diverse pathways
and cell types in the same disease [3–14]. While gen-
omic medicine has paved the way for addressing this di-
versity [15], the scale of the problem is indicated by
single-cell RNA-sequencing (scRNA-seq) studies, which
have shown altered expression of thousands of genes
across many different cell types [16–23]. While such
studies have resulted in the identification of potential
novel disease mechanisms, no single-cell type, pathway,
or gene has been shown to have a key regulatory role in
any disease. Instead, the dispersion of multiple causal
mechanisms across multiple cell types is supported by
several other studies [6, 8, 9, 24]. An extreme conse-
quence of such complexity could be that a prohibitive
number of drugs may be needed for effective treatment
of each disease. To address this problem, we would
ideally need to (1) characterize all disease-associated cell
types and pathways, followed by (2) prioritization of the
relatively most important. To our knowledge, neither of
these two challenges has been systematically addressed.
One reason is that many cell types may not be accessible
in patients, and another reason lack of methods to
prioritize between the cell types and pathways [24].
Here, we hypothesized that a solution to systematically
investigate multicellular pathogenesis and its diagnostic
and therapeutic implications could be to use scRNA-seq
data to construct models of disease-associated cell types,
their expression profiles, and putative interactions. We
will henceforth refer to such models as multicellular dis-
ease models (MCDMs). The importance of interactions
in an MCDM lies in that they link the cell types into
networks. As a simplified example, if the interactions
were unidirectional, they could be traced to find up-
stream cell types and mechanisms for therapeutic target-
ing. However, biological interactions are often more
complex. We therefore hypothesized that network tools
could be used to prioritize cell types, mechanisms, and
potential drug targets. In support, methods from
network science have been applied to analyze genome-
wide data from different diseases [25, 26]. We and others
have used such methods to identify biomarkers and
therapeutic targets based on bulk expression profiling
data of individual cell types [12, 27, 28], as well as to de-
velop a mathematical framework to rank network nodes
[29]. A core concept is that the most interconnected
nodes in a network tend to be most important. Indeed, a
large body of evidence supports that such analyses can
be formalized and used to find crucial nodes in a wide
range of systems, ranging from proteins essential for cell
survival to relevant web pages in a Google search [30,
31]. Because many cell types are not accessible from pa-
tients, we started with a mouse disease model. We fo-
cused on a mouse model of antigen-induced arthritis
(AIA), because it allows potential analysis of all cells in
the target organ, joints, and adjacent lymph nodes. We
used our recently developed method for translational
scRNA-seq [32]. The resulting MCDMs and comple-
mentary analyses of patients with RA and 174 other dis-
eases supported multicellular pathogenesis of great
complexity. Our analyses indicate that network analyses
of the MCDMs can help to prioritize cell types and
genes for diagnostics and therapeutics. General applic-
ability of our strategy was supported by prospective
diagnostic studies of 151 patients with 13 autoimmune,
allergic, infectious, malignant, endocrine, metabolic, and
cardiovascular diseases, as well as 53 age- and sex-
matched controls. The therapeutic potential of the strat-
egy was supported by network-based analyses of these
diseases, as well as a study of the mouse model of arth-
ritis. Taken together, our results support that our strat-
egy may have the potential to prioritize therapeutic and
diagnostic targets in complex diseases.
Methods
Study design
In summary, this study describes a scalable, step-wise
strategy to construct MCDMs and exploit them for diag-
nostics and therapeutics. The strategy was validated by
both clinical and experimental studies. The strategy is
based on applying network tools to organize and analyze
scRNA-seq data from a mouse model of arthritis and
human rheumatoid arthritis. Diagnostic validation stud-
ies were performed using expression profiling data and
potential protein biomarkers from prospective clinical
studies of 13 diseases. A candidate drug was examined
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by a treatment study of a mouse model of arthritis, using
phenotypic, immunohistochemical, and cellular analyses
as read-outs.
Mouse model of rheumatoid arthritis
In order to construct high-resolution multicellular disease
models (MCDMs), we first performed scRNA-seq analysis
in a mouse model of antigen-induced arthritis (AIA). This
model is suitable for generating MCDMs in an in vivo set-
ting because most disease-associated cell types and sub-
sets can be potentially identified in the inflamed joint and
adjacent lymph nodes. Arthritis was triggered in six anes-
thetized female 129/SvE mice (aged 8 to 20 weeks) on day
21 by intra-articular injection of 30 μg methylated bovine
serum albumin (mBSA) in 20 μL, in the left knee joint
after subcutaneous pre-sensitization with 100 μg mBSA in
incomplete Freund’s adjuvant and 200 μg mBSA in
complete Freund’s adjuvant two (day 7) and three (day 1)
weeks earlier, respectively. The right knee joint was
injected with 20 μL phosphate-buffered saline (PBS) as
negative control. In some experiments, mBSA was
injected in both joints to allow assessment of arthritis and
scRNA-seq data from joint cells from the same arthritic
animal. One week after intra-articular injection of mBSA
(day 28), mice were sacrificed, and joints were either used
for immunohistochemistry or scRNA-seq. For assessment
of the degree of arthritis, joints were routinely fixed in 4%
paraformaldehyde (PFA), decalcified in formic acid/so-
dium citrate buffer, embedded in paraffin, and cut into 4-
μm-thick sagittal sections before hematoxylin and eosin
(H&E) staining, as described in [33]. Specimens were ex-
amined in a blinded manner for pannus formation, cartil-
age and subchondral bone destruction, and synovial
hypertrophy on an arbitrary scale, 0–3, as described in
[33]. Arthritis frequency (score one or higher) and arthritis
severity (median score) were calculated and compared to
non-arthritic controls using the Mann-Whitney U test. All
experimental procedures were performed according to the
guidelines provided by the Swedish Animal Welfare Act
and approved by the Ethical Committee for research on
animals in Stockholm, Sweden (N271-14). For scRNA-seq
experiments (see below), joints and lymph nodes from
naïve (control) and arthritic mice draining the sites used
for mBSA injection (axillary and popliteal) were isolated
and single-cell suspensions were prepared by triturating
the joint and lymph nodes and passing them gently
through a 70-μm cell strainer. Red blood cells were lysed
by adding RBC lysis solution (Sigma-Aldrich) according to
the manufacturer’s instructions.
Single-cell RNA-seq wet lab protocol
All scRNA-seq experiments were performed using the
Seq-Well technique [32]. Briefly, single-cell suspensions
prepared from cultured cells or tissue samples using
standard techniques were counted and co-loaded with
barcoded and functionalized oligo-dT beads (Chem-
genes, Wilmington, MA, USA; cat. no. MACOSKO-
2011-10) on microwell arrays synthesized as described in
[32]. For each sample, 20,000 live cells were loaded per
array, and libraries from three samples were pooled to-
gether for sequencing, resulting in a coverage of 6.6
reads per base. The microwell arrays were then covered
with previously plasma-treated polycarbonate mem-
branes, and the membranes were allowed to seal to the
bead and cell co-loaded microwell arrays at 37 °C for 30
min. Next, cell lysis and hybridization were performed,
followed by bead removal, reverse transcription, and
whole transcriptome amplification. Libraries were pre-
pared for each sample using the Nextera XT DNA Li-
brary Preparation Kit (Illumina, San Diego, CA, USA;
cat. no. FC-131-1096) according to the manufacturer’s
instructions. Libraries were sequenced using the Next-
Seq 500/550 system, and sequencing results were ana-
lyzed as described below.
Validation of the single-cell RNA-seq analytical process
To verify our scRNA-seq setup, we mixed the two colo-
rectal cancer (CRC) cell lines SW480 and HT29 before
application to the single-cell array and sequenced them
altogether according to the procedures described above.
These two CRC cell lines (SW480 and HT29) were a
kind gift from Xiaofeng Sun (Linkoping University). We
showed that the cells from our previously mixed cell
lines were correctly assigned to their corresponding cell
lines, verifying our single-cell sequencing and clustering
methods (Additional file 1: Figure S1). Quality check
and clustering was performed as described below, using
26 colon cancer cell lines profiled with microarrays
(GSE10843). Here, a low cutoff of 4000 unique tran-
scripts per cell was added as a criterion to Seurat (Add-
itional file 1: Figure S2). In total, 233 cells passed the
quality criteria and were separated into two main clus-
ters: SW480 and HT29, as expected. However, a sub-
cluster of SW480, with a profile resembling that of the
SW620 CRC cell line, was also identified (Additional file
1: Figure S1).
Single-cell RNA-seq data processing
The single-cell data was processed into digital gene ex-
pression matrices following James Nemesh, McCarrol’s
lab Drop-seq Core Computational Protocol (version
1.0.1, http://mccarrolllab.com) using bcl2fastq Conver-
sion and Picard software. The indexed reference for
alignment of the reads was generated from GRCh38
(April 2017, Ensembl) for human data (validation of the
wet lab and cell type identification protocols; see the
“Methods” section) and GRCm38 (June 2017, Ensembl)
for mouse data using STAR software. Only primary
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alignments towards the reference genome were consid-
ered during downstream analyses, according to the map-
ping quality using STAR software. The quality of cells
was assessed by having a minimum of 10,000 reads, 400
transcripts, and less than 20% mitochondrial genes per
cell. Outliers were then removed based on an overesti-
mation of transcripts count, due to the risk of duplicates
in the library resulting in two or more cells sharing a cell
barcode. This resulted in a total of 7086 and 1333 cells
for the joint and lymph node data, respectively. The sin-
gle-cell data was then normalized using Seurat [34] for
further analysis. To reduce the noise within the data, K-
nearest neighbor smoothing was applied for each tissue
matrix separately, using a minimum k of 5 or, if more
than 5000 cells were captured, ~ 0.1% of the total num-
ber of cells [35].
Cell type identification
To cluster the cells and define the cell types, reference
component analysis (RCA) was performed [18]. Each cell
was projected against reference bulk expression profiling
data, which were generated or derived from public data-
bases, as described for each dataset below. The RCA ref-
erences were prepared as described in the original paper
[18]. Briefly, all genes with log10 (fold change) expres-
sion values greater or equal than 1 in any sample, rela-
tive to the median across all samples, were included. For
each cell, we also saved the Pearson correlation p value
from the RCA algorithm. Next, the reference component
features were calculated, and data were clustered in a
stepwise procedure. First, cells were clustered as de-
scribed above. Second, those cells with non-significant p
values (p > 0.05) were removed. Cells within each cluster
that were significantly correlated (Benjamini-Hochberg
adjusted p < 0.05) with their RCA-predicted cell type
were identified accordingly, and cells with non-signifi-
cant correlations were labeled as undetermined.
To construct the reference for the cell type identifica-
tion in mouse experiments, we used the data from the
study GSE10246. The resulting reference contained 5030
genes and 31 cell types/states (Additional file 2). t-SNE
plots of joint and lymph node cells were created using
MATLAB function tsne(), with perplexity parameter set
to 40, based on the distance matrix obtained from RCA.
Cells were colored according to the clusters identified
with RCA. For clustering of the CRC cell lines, a refer-
ence was constructed using microarray data from
GSE10843 and the same parameters as for the mouse
reference. The resulting reference contained 2303 genes
and 26 different cell lines (Additional file 2).
Identification of differentially expressed genes
For single-cell data, differentially expressed genes
(DEGs) were identified between each cell type and all
other cell types, within each tissue separately, using
Monocle (version 2.6.1) [36, 37]. A negative binomial
distribution was used to define the dataset with a lowest
detection limit of 0.5. Genes detected in at least three
cells within a group were considered as expressed. Genes
were considered as significantly differentially expressed
if the q value < 0.05. For microarray data, DEGs were
identified using the LIMMA R package.
Pathway, biomarkers, and drug target enrichment
analyses
Identification of pathways, biomarkers, and therapeutic
targets was done with Ingenuity Pathway Analysis soft-
ware [38].
Network construction and centrality analysis
Our work included the different analysis of two kinds of
cell-cell interaction networks, where one is based on po-
tential spatial interactions and the other on predicted
molecular interactions (see details below). The former
was used as a proxy for molecular interactions, either
because the cell types were not accessible from human
patients or to prioritize cell types and tissues for scRNA-
seq studies in animal models or human patients. We
have made the resulting models of each 175 diseases
available for such prioritization. The spatial interaction
network models were created by empirical knowledge of
which cells could potentially interact in the body. Sec-
ond, using scRNA-seq data, we derived a refined net-
work models, MCDMs, in which interactions were based
on possible regulatory molecular interactions. These
were inferred using Ingenuity upstream regulation ana-
lysis of the differentially expressed genes in each cell
type. We validated the inferred interactions by another,
recently described method, which is based on ligand-re-
ceptor interactions. However, both cases represent net-
works of possible physical interactions between cell
types. The spatial network represented an undirected
average network consisting of more nodes (45 cell
types), while the latter resulted in a more sophisticated
weighted and directed network of fewer nodes (e.g., six
cell types for the joint MCDM from mouse AIA). There
are many different methods to measure centrality. Given
that we have no information about the kind of paths in
the MCDM that will provide the best functional repre-
sentation of the underlying chain of gene-regulatory pro-
cesses, and that testing many different methods would
involve risk of over-parametrization, we assumed a max-
imum entropy principle and used the less biased theoret-
ical-information approach that for navigation is random
walk centrality [39]. This metric is based on the average
length of an average random walker moving at the net-
work considering the weights, which has also been used
by others in molecular biology. As our work aimed for
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using centrality as a generalizable concept, we also
tested other metrics, such as the subgraph closeness
centrality that is based on that the flow is concentrated
to the closest paths. We found that although less signifi-
cant similar results held for this metric as well. In sup-
port of centrality analyses to prioritize cell types, we
found tumor cells to be most central in scRNA-seq data
from colorectal cancer and significant correlations be-
tween centrality in scRNA-seq data from both mouse
AIA and human RA.
Construction of MCDMs
We constructed the MCDMs using scRNA-seq data
from colorectal cancer, mouse AIA (sick or healthy
lymph nodes and joints), and human RA synovium.
The MCDMs showed genome-wide mRNA expres-
sion of each cell type as well as potential types and
directions of intercellular interactions. For MCDM
construction, we started by identifying cell-type-spe-
cific genes, i.e., DEGs in one cell type compared
with all others, using the methods described above.
Using those gene lists, MCDMs were constructed.
First, the Ingenuity Pathway Analysis (IPA) software
was queried for prediction of the upstream regula-
tors of cell-type-specific DEGs for each cell type sep-
arately. Here, we focused on upstream regulators
that were secreted or membrane-bound. Next, we
searched for predicted upstream regulators among
the DEGs of other cell types. If such an upstream
regulator was found, an interaction was assumed be-
tween the cell types.
To systematically validate the MCDM cellular interac-
tions derived from Ingenuity, we used the novel Cell-
PhoneDB [40] framework. CellPhoneDB is a publicly
available curated repository of ligands, receptors, and
their interactions, which integrates a statistical tool for
the inference of cell-cell communication networks from
human single-cell transcriptomic data. Specifically, cell-
type interactions between ligands and receptors from
mouse RA and healthy joint MCDMs, and mouse RA
lymph node MCDM were analyzed with CellPhoneDB,
using the default parameters (the ligands and receptors
included should be expressed in at least 10% of the cells
for each cluster, and the cluster labels of every cell were
randomly permuted 1000 times). As CellPhoneDB is de-
veloped for human scRNA-seq data, mouse genes were
mapped to human orthologs using the BioMart database
[41]. In total, 6203 (82.2%) and 4808 (87.4%) mouse
genes from RA and healthy joint, respectively, could be
mapped to humans. An interaction between two cell
types was considered significant if the CellPhoneDB ana-
lysis predicted any interaction between the cell types
with a significance score of p < 0.05.
Cell centrality analysis
Cell centrality was determined by the random walk cen-
trality and subgraph centrality [39]. For the scRNA-seq
MCDM, directions were derived from the IPA upstream
regulatory analysis, and weights were added to the inter-
actions to include biological information for the compu-
tation of the coefficient. The weights were based on the
number of cells of each cell type and its number of pre-
dicted upstream regulators (as described in the “Con-
struction of MCDMs” section). The assumption behind
these weights is that the chances of interactions between
cell types are likely to increase with the number of cells
and upstream regulators. Specifically, the weight for each
interaction was derived by multiplying the number of
cells by the number of predicted upstream regulators for
two interacting cell types. Finally, the centrality of each
cell was determined by the subgraph centrality using the
normalized weighted adjacency matrix [42]. In order to
validate that centralities were not biased by our choice
of the Ingenuity database, we recomputed MCDMs and
centrality measures using publicly available ligand-recep-
tor interactions in mice [43] instead of Ingenuity.
Centrality analysis of MCDMs from colorectal tumors
The hypothesis behind these analyses was that, since
tumor cells have a causal role, they should also be more
central than the surrounding immune and stromal cells.
To test this hypothesis, processed FPKM (fragments per
kilobase of transcript per million reads mapped) values
for a scRNA-seq experiment of colon cancer
(GSE81861) were downloaded from Gene Expression
Omnibus [18]. T cells, B cells, and undefined cells were
re-clustered using RCA, generating a novel reference ex-
pression profiling compendium. This consisted of 49 mi-
croarrays profiling 11 samples: B cell, CD4+, CD8+,
monocytes, natural killer cells, naïve T cells, PBMC, Th1,
Th17, Th2, and T regulatory (Treg) cells. Microarrays
were processed as described below. RCA reference was
prepared as described above, i.e., following instructions
in [18]. Briefly, we included all genes with log10 (fold
change) expression values above one in any sample, rela-
tive to the median across all samples. For each cell, we
saved the correlation p value from the RCA algorithm.
Next, we checked if all cells within each cluster were sig-
nificantly correlated (BH adjusted p < 0.05) with the
RCA-predicted cell type from reference data. All cells
that did not fulfill this requirement were labeled as un-
determined. In total, 579 cells were analyzed (Additional
file 2). The DEGs were identified using Monocle and a
truncated normal distribution (tobit) owing to its FPKM
format, and the lowest detection limit was set at 0.1.
The estimateSizeFactors() function was used to
normalize for differences in mRNAs recovered across
cells, and genes that were expressed in at least three
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cells were considered as present within a group. A
tumor MCDM was constructed and centrality analyses
were performed as described above (Additional file 1:
Figure S3).
Generation of an expression profiling reference
compendium of immune cells
This compendium was used as a reference for classifying
cell types in the scRNA-seq data from colorectal cancer
and for deconvolution analyses of expression profiling
data from CD4+ T cells. PBMCs were isolated from hu-
man peripheral blood using Lymphoprep (Axis-Shield
Density Gradient Media, Oslo, Norway; cat. no.
1114545) according to the manufacturer’s instructions.
Total RNA was extracted from one million PBMCs for
microarray analysis. CD4+ T cells were isolated from
two thirds of the remaining PBMCs using the CD4+ T
Cell Isolation Kit, human (Miltenyi Biotec, Bergisch
Gladbach, Germany; cat. no. 130-096-533) and LS Separ-
ation Columns (Miltenyi Biotec, Bergisch Gladbach,
Germany; cat. no. 130-042-401) according to the manu-
facturer’s instructions. The negative fraction contained
the CD4+ T cells. Total RNA was extracted from one
million CD4+ T cells for microarray analysis. Remaining
of the CD4+ T cells were incubated with anti-human
CD4-FITC (Miltenyi Biotec, Bergisch Gladbach,
Germany; cat. no. 130-092-358), anti-human CD127-PE
(Becton, Dickinson, Franklin Lakes, NJ, USA; cat. no.
561028), anti-human CD183 (CXCR3)-PerCP/Cy5.5
(Biolegend, San Diego, CA, USA; cat. no. 353713), anti-
human CD196 (CCR6)-PE/Cy7 (Biolegend, San Diego,
CA, USA; cat. no. 353417), anti-human CD45RA-APC
(Biolegend, San Diego, CA, USA; cat. no. 304111), anti-
human CD25-APC/Cy7 (Biolegend, San Diego, CA,
USA; cat. no. 302613), and anti-human CD194 (CCR4)-
PE/Dazzle (Biolegend, San Diego, CA, USA; cat. no.
359419) for fluorescence-activated cell sorting (FACS) of
naïve CD4+ T cells (only for counting, CD4+CD45RA+),
Th1 (CD4+CXCR3+CCR6-CCR4-), Th2 (CD4+CXCR3-
CCR6-CCR4+), Th17 (CD4+CXCR3-CCR6+CCR4+),
and Treg (CD4+CD127lowCD25hi) cells. The remaining
third of the PBMCs was used to isolate naïve CD4+ T
cells using the Naïve CD4+ T Cell Isolation Kit II, hu-
man (Miltenyi Biotec, Bergisch Gladbach, Germany; cat.
no. 130-094-131) and LS Separation Columns (Miltenyi
Biotec, Bergisch Gladbach, Germany; cat. no. 130-042-
401) according to the manufacturer’s instructions. The
negative fraction contained the naïve CD4+ T cells (NT
cells). Total RNA was extracted from NT cells for micro-
array analysis. The positive fraction from NT magnetic
isolation was pooled with the positive fraction from
CD4+ T cell magnetic isolation and incubated with anti-
human CD3-Pacific Blue (Biolegend, San Diego, CA,
USA; cat. no. 300418), anti-human CD4-FITC (Miltenyi
Biotec, Bergisch Gladbach, Germany; cat. no. 130-092-
358), anti-human CD56 (NCAM)-PE (Biolegend, San
Diego, CA, USA; cat. no. 318305), anti-human CD19-
PerCP/Cy5.5 (Biolegend, San Diego, CA, USA; cat. no.
302229), anti-human CD14-PE/Cy7 (Biolegend, San
Diego, CA, USA; cat. no. 325617), and anti-human CD8-
APC (Becton, Dickinson, Franklin Lakes, NJ, USA; cat.
no. 555369) antibodies for FACS of CD4+ (only for
counting, CD3+CD4+) and CD8+ (CD3+CD8+) T cells,
natural killer cells (CD56+), B cells (CD19+), and mono-
cytes (SSClowCD14+). Total RNA was isolated from 11
cell types (PBMCs, B cells, CD4+ and CD8+ T cells,
monocytes, natural killer cells, naïve T cells, Th1, Th17,
Th2, and Treg cells using the AllPrep DNA/RNA Micro
kit (Qiagen, Hilden, Germany; cat. no. 80284) according
to the manufacturer’s instructions and used for micro-
array analysis.
Cell centrality correlation with enrichment of genes
harboring RA-associated genetic variants
Pearson correlation was calculated between subgraph cen-
trality score and −log(p value) of the enrichment of genes
harboring RA-associated genetic variants among the
DEGs in each cell type. Genes harboring genetic variants
associated with RA were downloaded from DisGeNet
(February 2017), one of the largest publicly available col-
lections of genes and genetic variants associated with hu-
man diseases (http://www.disgenet.org) [44]. We removed
two long non-coding RNA, 21 gene symbols beginning
with LOC, and three microRNAs, leaving 207 genes. Since
the RA-gene associations were identified in human sam-
ples and RA cells were derived from a mouse model, we
searched for mouse orthologs for all human RA-associ-
ated genes. The list of human and mouse orthologs was
downloaded from Ensembl Compara in June 2017
(Ensembl version 89). For 169 out of 207 human RA asso-
ciated genes, we identified mouse orthologs.
Enrichment of human RA-associated genes in mouse
MCDMs
Since RA-gene associations were identified in human
samples and RA cells were derived from a mouse model,
we used mouse orthologs for all genes harboring genetic
variants associated with RA. The 169 mouse orthologs
were used for enrichment (Additional file 2). As a back-
ground, we used all mouse genes annotated in the NCBI
database on June 16, 2017. Enrichment results are re-
ported in (Additional file 3: Tables S1 and S2).
Identification of disease-associated genes and cell types
by meta-analysis of genome-wide association studies and
cell-type-specific epigenetic markers
We first identified diseases analyzed with genome-wide
association studies (GWAS) by downloading GWAS
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data compiled by the National Human Genome Re-
search Institute (NHGRI). First, we manually classified
180 traits as diseases (Additional file 2) and excluded the
remaining traits from the analysis. The identified dis-
eases belonged to 20 out of 21 disease chapters listed in
ICD-10-CM (International Classification of Diseases,
Tenth Revision, Clinical Modification, Additional file 2,
Additional file 3: Table S3): infectious (I); neoplasms (II);
diseases of the blood and blood-forming organs includ-
ing immune mechanisms (III); endocrine, nutritional,
and metabolic diseases (IV); mental and behavioral dis-
orders (V); diseases of the nervous system (VI); diseases
of the eye (VII); diseases of the ear (VIII); diseases of the
circulatory system (IX); diseases of the respiratory sys-
tem (X); diseases of the digestive system (XI); diseases of
the skin (XII); diseases of the musculoskeletal system
and connective tissue (XIII); diseases of the genitouri-
nary system (XIV); pregnancy, childbirth and the puer-
perium (XV); conditions originating in the perinatal
period (XVI); congenital malformations, deformations,
and chromosomal abnormalities (XVII); symptoms,
signs, and abnormal clinical and laboratory findings, not
elsewhere classified (XVIII); injury, poisoning, and cer-
tain other consequences of external causes (XIX); and
factors influencing health status and contact with health
services (XXI). One hundred seventy-five of the diseases
belonged to all 17 disease-associated chapters, while five
diseases belonged to chapters XVIII, XIX, and XXI. The
number of diseases in each ICD-10-CM chapter is illus-
trated in (Additional file 1: Figure S4).
Next, we downloaded single nucleotide polymor-
phisms (SNPs) associated with these diseases from Dis-
GeNet (February 2017) [44], which integrates 46,589
unique SNPs from GWAS, expert-curated repositories,
and scientific literature. In total, 9880 out of 46,589
SNPs (21.2%) were associated with the given 180 dis-
eases (Additional file 2). Among these, 8316 SNPs were
mapped to 4475 unique genes (3518 with Entrez
identifier).
In order to identify cell types significantly associated
with GWAS diseases, we selected cell types with cell-
type-specific epigenetic markers significantly enriched
for SNPs associated with each disease (Additional file 2).
These cell types and their disease associations were
compiled into a compendium, which will henceforth be
referred to as CellComp (Additional file 1: Figure S5).
First, we downloaded the processed BED files from EN-
CODE (https://www.encodeproject.org) for each of the
cell types corresponding to healthy cells, which in total
contained 45 cell types. We focused on nine epigenetic
markers that are present in most cell types (Additional
file 2). These cell types included those of the nervous,
immune, and circulatory systems, as well as stromal and
tissue-specific cell types.
GWAS disease SNPs overlapping with epigenetic
markers were used to calculate a disease-cell type p
value for each marker-disease-cell type triplet, using the
Fisher exact test. Specifically, each disease was defined
by the SNPs from DisGeNet (see above) in combination
with all linkage disequilibrium (LD) SNPs associated
with the disease SNP set, obtaining 175 out of the 180
diseases considered. LD SNPs were retrieved from SNAP
(https://www.broadinstitute.org/snap/snap) using the R
package “rsnps” with default parameters of R2 = 0.8,
within 500 base pairs for each SNP. For each cell type
and disease pair, we calculated an overlap Fisher exact p
value. For each marker, we then formed a disease-disease
similarity score based on similarities in their epigenetic
associations by Pearson correlation of −log p values of
the disease-epigenetic profiles, which resulted in a p
value for the disease-disease associations for each disease
pair and each marker. We then computed the direct
genetic overlaps of all diseases and found them to be
highly significant, although the marker with the lowest p
value was H3K36me3 (Additional file 3: Table S4). For
robustness analysis, we also computed a binomial en-
richment test by counting the numbers of significant dis-
ease-cell associations (Fisher’s exact test, p < 0.05), which
also showed significant enrichment for many markers.
We performed the analysis by constructing a single epi-
genetic disease association score for each of the 45 cell
types and 175 diseases by combining each of the p
values from the markers using the Fisher method (also
known as Fisher’s combined probability test method).
Using this score, we found a significant association
(Fisher’s exact test, p < 0.05) of each disease with a me-
dian range of 20 (0–45) cell types (Additional file 3:
Table S4). The disease-cell associations are shown in a
cluster diagram (Additional file 1: Figure S6).
Pathway analysis of genes harboring disease-associated
genetic variants
In order to identify the potentially most disease-relevant
cell types in the MCDMs, we performed pathway ana-
lysis of the genes harboring genetic variants associated
with the GWAS diseases, using the IPA software (Add-
itional file 1: Figure S7). We found that the most signifi-
cant pathways were immune-related, including the top
scoring Th1 and Th2 activation pathway (p = 3.22 ×
10−34). To examine if this result was caused by an over-
representation of immune-related GWAS diseases, a
medical doctor manually classified the diseases as either
primarily immune or non-immune (Additional file 2).
Then, we repeated the analyses for all primary non-im-
mune-related diseases. This also resulted in the identifi-
cation of the Th1 and Th2 activation pathway as one of
the top scoring pathways (p = 3.33 × 10−14).
Gawel et al. Genome Medicine           (2019) 11:47 Page 7 of 25
Construction of a cell type-disease network
To get an overview of the disease-associated cell types,
we constructed a network where cell types were depicted
as nodes with sizes proportional to the number of dis-
eases they were associated with. The nodes were linked
based on manual curation of potential spatial interac-
tions in the body. For example, bronchial epithelial cells
can spatially interact with T lymphocytes but not with
uroepithelial cells (Additional file 2).
In the resulting network, immune cells were most in-
terconnected and also appeared to be associated with
more diseases than less connected cells. Indeed, we
found a significant positive correlation between the de-
gree of the cell type and the number of diseases a cell
type was associated with (from the epigenetic association
score, Pearson r = 0.31, p = 0.038). Moreover, we classi-
fied all cell types into cell categories, namely immune
cells, epithelial cells, muscle cells, neural cells, hepato-
cytes, fibroblasts, and osteoblasts (Additional file 2). For
each cell category, we calculated a general cell-class-dis-
ease association p value by Fisher combining p values
for all diseases and all cell types in cell category. Small p
values from the chi-square distribution were numerically
approximated through a normal distribution approxima-
tion followed by Taylor series expansion of the cumula-
tive probability distribution [35].
Public profiling data of CD14+, CD4+, and B cells from
patients with rheumatoid arthritis
For the construction of RA modules based on expression
profiles in CD14+, CD4+ T cells, and B cells, we down-
loaded public microarray experiments from GEO. We
analyzed the datasets GSE57386 (CD14+), GSE56649
(CD4+ T cells), and GSE4588 (B cells). Module con-
struction and classification with elastic net were per-
formed as described below.
Prospective clinical expression profiling studies of CD4+ T
cells from patients with 13 different diseases
We conducted prospective clinical studies to validate the
importance of CD4+ T cells in 13 diseases from the fol-
lowing ICD-10-CM chapters: neoplasms (breast cancer,
chronic lymphocytic leukemia); endocrine, nutritional,
and metabolic diseases (type I diabetes, obesity); diseases
of the circulatory system (atherosclerosis); diseases of
the respiratory system (acute tonsillitis, influenza, sea-
sonal allergic rhinitis, asthma); diseases of the digestive
system (Crohn’s disease, ulcerative colitis); and diseases
of the skin and subcutaneous tissue (atopic eczema,
psoriatic disease).
Study participants were recruited by clinical specialists
based on diagnostic criteria defined by organizations
representing each specialist’s discipline. Age- and gen-
der-matched healthy controls (n = 151 and 53,
respectively) were recruited in the Southeast region of
Sweden from outpatient clinics at the University Hos-
pital, Linköping; Ryhov County Hospital, Jönköping, a
primary healthcare center in Jönköping; and a medical
specialist unit for children in Värnamo. Study partici-
pants represented both urban and rural populations with
an age range of 8–94 years. Patients with type I diabetes
and obesity had an age range of 8–18 years. Eleven pa-
tients had more than one diagnosis and are included in
the reported patient numbers in the following descrip-
tion. For the bioinformatic analyses, when comparing
patients with different diagnoses, patients suffering from
both diseases in question were excluded (for example,
when classifying patients with atherosclerosis versus in-
fluenza, patients having both of those diseases were ex-
cluded from this specific calculation).
ICD-10-CM chapter II: neoplasms
Breast cancer Patients with breast cancer were re-
cruited at first diagnosis at an outpatient clinic based on
clinical examination (palpation), radiological analyses
(mammography and ultrasonography), and pathologist’s
evaluation of biopsy material from mastectomy and sen-
tinel nodes. Blood sampling was performed before sur-
gery, and all included patients had invasive ductal or
lobular cancers. First, eight patients were recruited (me-
dian age [range], 73.5 [67–82] years). For a second valid-
ation study, an independent group of 24 patients
(median age [range], 61.5 [35–88] years) was recruited,
based on the same inclusion criteria. All recruited pa-
tients were women.
Chronic lymphocytic leukemia (CLL) Patients (n = 8;
three women; median age [range], 69.5 [51–80] years)
with untreated CLL were recruited from two
hematological outpatient clinics.
ICD-10-CM chapter IV: endocrine, nutritional, and metabolic
diseases
Type I diabetes mellitus Children and adolescents who
met the criteria defined by the International Society for
Pediatric and Adolescent Diabetes [8] were recruited,
i.e., fast-plasma-glucose level above 7.0 mmol/L at two
occasions, alternative non-fasting plasma glucose above
11.1 mmol/L, and symptoms of hyperglycemia. Patients
with type I diabetes or those who received insulin treat-
ment for more than 4 weeks were excluded (n = 8, two
females; median age [range], 12.5 [11–16] years).
Obesity Children who fulfilled international criteria for
overweight or obesity were included based on standards
for anthropometric measuring and those with diabetes
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mellitus were excluded [9]. Age- and gender-correlated
body mass index (BMI) was calculated and defined as
weight (kg) divided by stature square (m2). The median
BMI was 28.0 (23.0–39.5). In total, 17 patients were re-
cruited, including children (seven females; median age
[range], 14.0 [8–60] years).
ICD-10-CM chapter IX: diseases of the circulatory system
Atherosclerosis Patients were recruited by the same
surgeon based on standard criteria [45] at an outpatient
clinic, at least 3 months after coronary artery bypass
graft surgery. In total, 12 patients were recruited (two fe-
males; median age [range], 71 [49–80] years). The pa-
tients were on continuous medication with statins.
Patients with diabetes mellitus were excluded.
ICD-10-CM chapter X: diseases of the respiratory system
Acute tonsillitis Patients (n = 6, six females; median age
[range], 37.0 [26–46] years) with clinical signs of acute
tonsillitis were recruited, and the diagnosis was con-
firmed through a rapid antigen diagnostic test or throat
culture before the administration of antibiotics (n = 6).
Influenza Patients with influenza A (n = 9) and influ-
enza B (n = 1) were included in the study. Influenza
diagnosis was verified by PCR analysis on nasopharyn-
geal secretions using the Xpert Flu/RSV XC assay (Ce-
pheid, Sunnyvale, CA) according to the manufacturer’s
instructions. A total number of 10 patients were re-
cruited (four females; median age [range], 63.0 [23–97]
years). Blood samples were drawn while the patients
were still symptomatic. Most patients had not started
any antiviral therapy at the time of sampling, but some
had received one dose of oseltamivir.
Seasonal allergic rhinitis In total, 13 patients with sea-
sonal allergic rhinitis were recruited (11 females; median
age [range], 38.0 [19–53] years) based on clinical history
for at least two pollen seasons, and positive skin prick
tests or radioallergosorbent tests (RAST) for birch or
grass. Samples were obtained during the pollen season
after at least 1 day of symptoms and before treatment.
Asthma Patients were recruited based on standard cri-
teria, i.e., at least 2-year history of recurrent wheezing
and baseline bronchodilator reversibility of ≥ 12%. All
patients were treated with inhaled glucocorticoids and
bronchodilators as required. In total, 17 patients were
recruited (six females; median age [range], 49.0 [16–74]
years).
ICD-10-CM chapter XI: diseases of the digestive system
All patients with the inflammatory bowel diseases (IBDs)
UC and CD were recruited at a gastroenterology out-
patient clinic by the same gastroenterologist, based on
clinical evaluation, endoscopy, and/or MRI, as well as
characteristic histopathological findings and exclusion of
differential diagnosis.
Ulcerative colitis In total, 10 patients with UC (five fe-
males; median 515 age [range], 51.5 [20–69] years were
recruited.
Crohn´s disease In total, 11 patients with CD (nine fe-
male; median age [range], 516 50.0 [31–76] years) were
enrolled in the study.
All patients were in remission. None of the study sub-
jects had received any systemic immunosuppressive
medication three months prior to study entry.
ICD-10-CM chapter XII: diseases of the skin and
subcutaneous tissue
All atopic eczema and psoriasis patients were diagnosed
by the same dermatologist (OS), based on standard cri-
teria, medical history, and/or histopathological findings,
at a dermatology outpatient clinic.
Atopic eczema In total, nine patients (three females;
median age [range], 42.0 [12–76] years) were recruited.
Psoriasis In total, 11 patients (six females; median age
[range], 48.0 [20–71] years) with mild to severe plaque-
type psoriasis were recruited. Atopic eczema patients
had active eczema for at least 1 week, and a diagnosis
for at least 2 years. Psoriasis patients were diagnosed for
at least 1 year, and assessment of disease severity was
performed using the Psoriasis Area and Severity Index
(PASI). Median PASI was 8.1 (range, 4.2–16.2). None of
the study subjects had received any systemic immuno-
suppressive medication or phototherapy 3 months prior
to study entry.
Isolation of peripheral CD4+ T cells
Briefly, PBMCs were prepared from fresh blood samples
from the patients of 13 diseases and healthy controls, as
previously described [12], using Lymphoprep (Axis-
Shield PoC) according to the manufacturer’s protocol.
Total CD4+ T cells were enriched from PBMCs by
FACS. Human IgG (Sigma-Aldrich, St Louis, MO, USA)
at a final concentration of 200 μg/mL was used to block
cells prior to staining. Mouse anti-human CD4-FITC
(BD Pharmingen San Diego, CA, USA), Mouse antihu-
man CD3-Pacific Blue (Biolegend San Diego, CA, USA),
and all matched isotype controls were purchased. Cell
sorting was performed on a FACS Aria flow cytometer
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(BD Biosciences, San Diego, CA, USA), and the data was
analyzed by FlowJo 7.6 (Tree Star, Inc., San Carlos, CA).
After sorting, the purity of total CD4+ T cells was more
than 98%.
Preparation of RNA for expression profiling
Total RNA was extracted using the AllPrep DNA/RNA
Micro kit (Qiagen, Hilden, Germany; cat. no. 80284) ac-
cording to the manufacturer’s instructions. RNA concen-
tration and integrity were evaluated using the Agilent
RNA 6000 Nano Kit (Agilent Technologies, Santa Clara,
CA, USA; cat. no. 5067-1511) on an Agilent 2100 Bioa-
nalyzer (Agilent Technologies, Santa Clara, CA, USA).
Microarrays were then further computationally proc-
essed as described in One-Color Microarray-Based Gene
Expression Analysis Low Input Quick Amp Labeling
protocol (Agilent Technologies, Santa Clara, CA, USA).
Microarray data processing
All gene expression microarrays were processed as de-
scribed above using the LIMMA R package. All probes
with an expression below 1.2 times the background sig-
nal were removed. To test whether the sex or age of the
patients had any confounding effects on the CD4+ T cell
microarray data for the 13 diseases, a principal compo-
nent analysis (PCA) was performed. The results showed
no clear differences in any of the components (Add-
itional file 1: Figure S8). To test for possible confounding
effects within T cell subsets, we performed deconvolu-
tion analysis of expression profiles from the CD4+ T
cells using profiles from Th1, Th2, Th17, and Treg cells.
Those profiles were derived from the above-described
reference expression profiling compendium of human
immune cells.
Deconvolution of bulk CD4+ T cell data with sorted T cell
subsets using CIBERSORT
We tested whether T cell subtypes differed significantly
between sexes, ages, and diseases. For this purpose, we
performed in vivo sorting of nine different immune cell
types, where four were tested in this study, namely Th1,
Th2, Th17, and Treg cells, followed by microarray ana-
lysis. Next, we applied CIBERSORT [46] with default pa-
rameters using our own reference transcriptomics data
for each of the patients from our 13 diseases and the
controls. This showed a high overlap of the different age
groups, sexes, and diseases (Additional file 1: Figure S9).
Human protein interactome
STRING (v.10) [47] was used to construct the human
protein-protein interaction network (PPIn) as a repre-
sentation of the human protein interactome. All the in-
teractions with a confidence score greater than 0.7 were
considered, for both direct (physical) and indirect
(functional) interactions. The resulted network consisted
of 11,228 vertices (proteins) and 212,419 edges
(interactions).
Module construction
The module construction was based on the integration
of expression data for diseases and controls, and the
PPIn. Given a disease di, its associated module Mi was
defined by the set of genes with highly correlated expres-
sion patterns, forming cliques into the PPIn and
enriched for DEGs. Given the modules M1, ... , M13, the
shared interaction neighborhood [9] was defined as the
union of modules, comprising all the genes from all the
disease modules. The modules consisted of median 392
genes [201–735]. A full list of individual module genes
is provided in Additional file 2. Top canonical path-
ways enriched in module genes are reported in Add-
itional file 2.
Diagnostic potential of CD4+ T cell expression profiles
Classification of patients and controls was performed
using elastic net function lassoglm() on MATLAB in the
Statistics Toolbox, choosing lambda (λ) from the mini-
mum deviance of leave-one-out cross-validation starting
from all the measured genes of the platform. Prediction
p values of case versus controls were based on the leave-
one-out estimates. We calculated the area under the pre-
cision recall curve using the perfcurve() MATLAB func-
tion. The p values were calculated using the two-sided
Wilcoxon rank-sum testing on the classifier discriminant
function outputs.
For each of the 13 diseases, expression of disease-spe-
cific module genes separated patients from controls with
high accuracy (median AUC 0.98, range 0.82–1; median
p < 2.8 × 10−5, range 8.5 × 10−8 to 7.8 × 10−4). For ex-
ample, the AUC for breast cancer was 1 (p = 1 × 10−5).
An independent validation study of the module in 24
breast cancer patients and 14 healthy controls yielded an
AUC of 0.82; p = 1.7 × 10−3, which was significantly
higher than that for random genes (one-sided, permuta-
tion test, p < 3.7 × 10−258). We also found that the re-
spective module union genes separated patients with
different diagnoses from each other (median AUC 0.98,
range 0.27–1; median p < 1.0 × 10−3, range 1.32 × 10−5 to
0.69; Additional file 2). Box plot was created using
MATLAB boxplot() function with default settings. Out-
liers were defined by the algorithm underlying boxplot()
function, i.e., points were assumed to be outliers if they
were greater than q3 +w × (q3 − q1) or less than q1 −
w × (q3 − q1), where q1 is the 25th percentile, q3 is the
75th percentile, and w corresponds to ± 2.7σ and 99.3%
coverage according to the function description.
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Classification robustness was confirmed via 20 additional
classifiers
Classification robustness was confirmed via 20 additional
classifiers, namely, Coarse KNN, Cosine KNN, Fine
KNN, Cubic KNN, Weighted KNN, Medium KNN,
Complex Tree, Medium Tree, Simple Tree, Linear Dis-
criminant, Logistic Regression, SVM Coarse Gaussian,
SVM Cubic, SVM Fine Gaussian, SVM Linear, SVM
Medium Gaussian, SVM Quadratic, Ensemble Subspace
KNN, Ensemble Bagged Trees, and Ensemble Subspace
Discriminant, all implemented with MATLAB Classifica-
tion Learner App. AUC and p values were calculated as
described above. Training and fivefold cross-validation
were repeated 100 times. Average AUC and p values are
reported in Additional file 2.
Prioritization of genes with the highest predictive value
for classification
To rank genes based on their predictive value, random-
ized elastic net was performed. Randomized elastic net
was implemented as a modification of randomized lasso
[48] where the lasso technique was replaced with elastic
net as follows: for selected λ, and α = 0.5, data were per-
muted by adding random penalty factors from the inter-
val [1/α,1] for each predictor; model coefficients were
estimated (elastic net); 10,000 permutations were per-
formed; and predictors with non-zero coefficients in at
least one of the 10,000 permutations were selected
(Additional file 2).
Measurement of the proteins in CD and UC
We measured the levels of CXCL1, CXCL8, CXCL11,
CCL20, TNF-α, and IL-1β (see above) in the serum of 15
UC patients, 11 CD patients, and 20 healthy controls
using the U-PLEX Biomarker Group 1 (hu) assays, SEC-
TOR (1PL) (Meso Scale Discovery, Rockville, MD, USA;
cat. no. K15067 L-1) according to the manufacturer’s in-
structions. The U-PLEX technology (https://www.meso-
scale.com/en/products_and_services/assay_kits/u-plex_
gateway) can measure a maximum of 10 proteins at the
same time and requires only 25 μl from each sample.
The biomarker group used (cat. No. K15067 L-1) was
custom designed and only measured the six proteins of
interest stated above.
Drug target analysis of the shared interaction
neighborhood
In order to test the therapeutic relevance of the SIN,
we downloaded all drugs that had at least one known
target in human cells (n = 1790; out of which 1408
were approved) from approved and investigational
drugs from DrugBank (version 5.0.3). We then tested
whether the SIN was enriched for these drugs and
found the SIN genes to be significantly enriched for
these drug targets (n = 302; Fisher exact test OR 2.92;
p = 2 × 10−53). An important therapeutic implication is
that drugs targeting the SIN can be potentially used
for more than one disease.
Identification of drugs suitable for targeting the SIN
In order to identify drugs suitable for targeting the SIN,
we computationally predicted which of the 1790 drugs
would mainly target disease genes in the SIN. The pre-
dictions were based on prioritization of drugs in network
proximity to the disease genes within SIN [49]. Briefly,
we calculated the distance between direct drug targets
(T) and disease genes (G) within the SIN (M) on the
PPIn [47] using the shortest path distance measure (d):
dd G;Tð Þ ¼ 1Tk k
X
t∈T
ming∈Gd g; tð Þ:
Disease genes were defined as DEGs between patients
and controls, as well as genes harboring genetic variants
associated with each disease.
To assess the significance of the distance between
drugs and disease-associated genes in the SIN (dd), we
created a reference distribution corresponding to the ex-
pected distances using randomly selected groups of drug
targets and disease genes. We performed 1000 degree-
preserving randomizations using a binning approach
that grouped nodes with a certain degree interval to-
gether, such that there were at least 300 nodes in a bin.
Next, the average d and standard deviation of reference
d distribution were used to convert observed distance to
a normalized distance:
z G;Tð Þ ¼ dd G;Tð Þ−μdd G;Tð Þ
σdd G;Tð Þ
:
Subsequently, z-scores were transformed to p values
using MATLAB ztest() function, left-sided test (Add-
itional file 2). To further validate these results, we also
modified the approach from Guney et al. [49] by calcu-
lating the distance between direct drug targets (T) and
disease genes (G), and between disease genes and the
SIN (M) on the PPIn using the minimum shortest path
distance measure d
ddm G;M;Tð Þ ¼ 1Tk k
X
t∈T





minm∈Md m; gð Þ
 !
:
This modification takes into consideration disease
genes (defined as described above) that are not a part of
the SIN. To assess the significance of the distance be-
tween drug, disease genes, and the SIN (ddm), we per-
formed 1000 degree-preserving randomizations using
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binning approach, as described above. Next, the average
d and SD of reference d distribution was used to convert
observed distance to a normalized distance:
zm G;M;Tð Þ ¼
ddm G;M;Tð Þ−μddm G;M;Tð Þ
σddm G;M;Tð Þ
and z-scores were then transformed to p values as de-
scribed above (Additional file 2).
We identified five such drugs, which targeted nine out
of 13 diseases. We validated one of these drugs, the per-
oxisome proliferator-activated receptor (PPAR)-alpha
agonist bezafibrate, in a T cell-dependent mouse model
of rheumatoid arthritis described above, which was not
among the 13 diseases that were analyzed to construct
the SIN.
Treatment study of bezafibrate in a mouse model of RA
To test if bezafibrate could dampen inflammation, we
administered bezafibrate to 8- to 20-week-old female
129/SvE mice subjected to the antigen-induced RA
model, as described above. Bezafibrate (Sigma-Aldrich,
B7273) was dissolved overnight in dimethyl sulfoxide
(DMSO; 0.1 g bezafibrate/mL) and further diluted in
PBS before treatment. Three different treatment proto-
cols were used to test the effect of bezafibrate on arth-
ritis development: (1) systemically at pre-sensitization
days 1 and 7 (8 mg bezafibrate/kg included in the
immunization solution containing mBSA + Freund’s ad-
juvant, n = 5), (2) systemically by injections after trigger-
ing of arthritis (4 mg bezafibrate/kg in a total volume of
500 μL PBS, intraperitoneally on days 21, 24, and 26, n =
4), and (3) locally by a single intra-articular injection
(0.6 mg bezafibrate/kg included in the mBSA solution
used to trigger arthritis, n = 5). For all treatments, con-
trol mice subjected to antigen-induced arthritis (AIA,
n = 5) were injected in the same manner with the same
volume of PBS/DMSO used for bezafibrate delivery
(max 0.1% DMSO). Systemic delivery of bezafibrate after
triggering of arthritis prevented the development of
arthritis (Additional file 1: Figure S10). Next, we exam-
ined if bezafibrate delivery would have local effects. This
was done by local treatment with a single intra-articular
injection of bezafibrate. We also examined the effects of
bezafibrate delivery at antigen sensitization: neither
treatment locally or at sensitization had any ameliorating
effects on arthritis (Additional file 1: Figure S10). To val-
idate the effects of bezafibrate on T cell proliferation, we
proceeded with a proliferation assay, as described below.
CD4+ T cell proliferation assay
Spleen and lymph nodes draining sites of injection (axil-
lary and popliteal) were isolated, and single-cell suspen-
sions (splenocytes and lymph nodes combined) were
prepared by passing the spleen and lymph nodes gently
through a 70-μm cell strainer. Red blood cells were lysed
by adding RBC lysing solution (Sigma-Aldrich) according
to the manufacturer’s instructions. Carboxyfluorescein
diacetate succinimidyl ester (CFDA-SE, Sigma-Aldrich) at
5 μM was added to cells and incubated for 5min in the
dark at room temperature (RT, 25 °C). This was followed
by washing the stained cells five times with FACS buffer
(PBS + 1% FBS). Stained cells (2 × 106/mL in a total vol-
ume of 200 μL) from mice subjected to AIA, mice sub-
jected to AIA, and treated with Bezafibrate as described
above and from naïve control mice were stimulated with
mBSA (50 μg/mL) and cultured for 72 h at 37 °C in 5%
CO2 and 95% humidity. After 72 h, cells were harvested
and analyzed for diminished carboxyfluorescein succini-
midyl ester (CFSE) stain by FACS. CFSE-stained, non-
stimulated cells from a naïve mouse were used to define
non-proliferating cells [50].
Proliferation assay
To determine the effect of bezafibrate on T cell prolifer-
ation in the RA model, spleen, axillary, and popliteal
lymph node cells from naïve, bezafibrate-treated, and
non-treated controls subjected to AIA were stained with
5 μM CFDA-SE (Sigma-Aldrich) by incubation for 5 min
in the dark at RT. Stained cells were washed five times
with FACS buffer (PBS + 1% FBS). Stained cells (2 × 106/
mL in a total volume of 200 μL) were stimulated with
mBSA (50 μg/mL) and cultured at 37 °C in 5% CO2 and
95% humidity. After 72 h, cells were harvested and ana-
lyzed for diminished CFSE-stain by FACS; see gating
strategy (Additional file 1: Figure S11) CFSE-stained cells
from a naïve mouse were used to define non-proliferat-
ing cells [50]. Assessment of antigen recall responses of
CD4+ T helper cells among spleen and lymph node cells
showed that the systemic intraperitoneal treatment with
bezafibrate that protected from arthritis also inhibited
proliferation of CD4+ T helper cells, which was not the
case for bezafibrate treatment locally or at sensitization
(Additional file 1: Figure S10). Thus, the protective effect
of bezafibrate on arthritis development is contingent on
its ability to inhibit T helper cell proliferation.
Results
scRNA-seq study of a mouse model of arthritis shows
wide dispersion of pathogenic mechanisms in multiple
cell types
We performed scRNA-seq analyses of a mouse model of
RA, antigen-induced arthritis (AIA). In this model, arth-
ritis is triggered by intra-articular injection of the anti-
gen mBSA in mice previously sensitized with mBSA
(Fig. 1a). Histologically, the arthritic tissue resembled
that found in human RA, with infiltration of inflamma-
tory cells into the synovium, cartilage/bone destruction,
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Fig. 1 (See legend on next page.)
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and hyperplasia of the synovial lining (Fig. 1b). scRNA-
seq was performed on whole arthritic joints, as well as
on joint lymph nodes (Fig. 1c). In total, we recovered
8420 single cells after filtering on a minimum of 10,000
reads and 400 transcripts per cell. Cell type classification
was performed using Reference Component Analysis,
RCA (see the “Methods” section) [18]. This method uses
bulk expression profiles of known cell types as refer-
ences to classify single-cell profiles based on genome-
wide transcriptional similarity. We first tested RCA by
analyzing if it correctly classified in-house scRNA-seq
data from two cancer cell lines using bulk profiling data
from 26 cell lines as a reference and found that this was
the case (see the “Methods” section, Additional file 1:
Figure S1). We next used RCA to classify cell types in
our mouse scRNA-seq data. We identified nine cell
types in arthritic mice and seven in healthy controls
(Fig. 1d, Additional file 1: Figures S12 and S13). The cell
types were dendritic cells, CD4+T lymphocytes, T regu-
latory cells (Treg), B lymphocytes, macrophages, granu-
locytes, common myeloid progenitor cells (promyeloids),
adipocytes, and osteoblasts. These cell types are similar
to those primarily or secondarily involved in human RA
[23, 51, 52] and are partially similar to cell types identi-
fied by scRNA-seq analysis of synovium from patients
with rheumatoid arthritis (RA) [23, 52]. In order to iden-
tify and prioritize mechanisms for therapeutic targeting,
we first identified differentially expressed genes (DEGs)
using Monocle. Similar to the scRNA-seq study of hu-
man RA [23], DEGs were calculated for each cell type
compared to all other cell types in each tissue separately
(see the “Methods” section). We performed pathway
analysis of the DEGs in AIA using the Ingenuity Path-
way Analysis (IPA). The most significant pathways
enriched among differentially expressed genes were
found in T cells and related to T cell activation and dif-
ferentiation, e.g., Cd28 signaling in T helper cells (p =
2.51 × 10−12 and Th1 differentiation (p = 5.75 × 10−9).
These pathways included genes with key roles for activa-
tion and differentiation, such as Il2, Itk, and Ifngr1.
Intuitively, therapeutic targeting of genes in the most
significant pathways would appear ideal. Indeed, drugs
that inhibit Th1- or Th17-like responses have been de-
veloped to treat RA [53]. However, those drugs have
shown variable efficacy [54]. One reason could be the in-
volvement of multiple other pathways in T cells and
other cell types, which are not targeted. Indeed, the
other most significant T cell pathways were highly di-
verse, e.g., calcium-induced T lymphocyte apoptosis
(p = 1.48 × 10−10), Nfat activation (p = 2.13 × 10−9),
Cdc42 signaling (p = 5.37 × 10−8), Nur77 signaling in T
lymphocytes (p = 3.47 × 10−7), and production of nitric
oxide and reactive oxygen species (p = 3.55 × 10−6). A
similar, and non-overlapping, diversity was found in
granulocytes, e.g., virus entry via phagocytosis (p =
1.29 × 10−9), Mtor signaling (p = 1.29 × 10−9), integrin
signaling (p = 6.91 × 10−8), leukocyte extravasation (p =
5.12 × 10−6), caveolar-mediated endocytosis (p = 1.12 ×
10−5), and Vegf signaling (p = 3.02 × 10−5). Further ana-
lyses of all differentially expressed genes in all the cell
types showed a great variety of pathways, therapeutic
targets, and biomarkers: 285 pathways, 263 drugs, and
873 biomarkers were significantly associated with any of
the cell types (p < 0.05). The median number of path-
ways per cell type was 46 (0–205), and the median num-
ber of cell types associated with each pathway was 2 (1–
8), (Additional file 2). This diversity suggested that spe-
cific therapeutic targeting of the most significant path-
way in one cell type would not suffice because of
multiple other pathways in the same or other cell types.
Instead, an impractical number of drugs targeting mul-
tiple pathways might be needed. Indeed, the number of
drugs predicted to target significant pathways in each
cell type was 55.5 (0–144), and the number of cell types
predicted to be targeted by each drug was 1 (1–8). Only
one drug, sirolimus, targeted most of the identified cell
types. This is a potent immunosuppressant, which has
been tried in refractory cases of RA, but has significant
side effects [55]. We repeated the above analyses in
cell types identified by scRNA-seq of human syno-
vium from patients with RA [23]. Similar to the AIA
mice there was a great diversity of pathways, which
were dispersed across multiple cell types. There were
also highly significant pathway overlaps between the
same cell types in human and mouse data (Additional
file 1: Figure S14, Additional file 2). Effective drug
targeting of such complex changes is a formidable
challenge, which may explain why many patients with
autoimmune diseases do not respond to treatment.
This highlights the need for novel, systems-level ap-
proaches to prioritize cell types and pathways for
therapeutic targeting.
(See figure on previous page.)
Fig. 1 scRNA-seq analysis of a mouse model of antigen-induced arthritis (AIA). a An overview of the AIA mouse model. b Representative joint
images from naïve mice and arthritic joints after hematoxylin and eosin (H&E) staining. B, bone marrow; S, synovial cavity; C, cartilage. Arrows
indicate (1) infiltration of inflammatory cells to the synovium, (2) cartilage/bone destruction, and (3) hyperplasia of the synovial lining. c A
schematic overview of seq-well scRNA-seq and cell type identification using reference component analysis (RCA). d t-SNE plot of 7086 healthy
and RA joint cells (n = 4 healthy mice samples and 5 sick mice samples), and 1333 healthy and AIA lymph nodes cells (n = 4 healthy mice
samples and 5 sick mice samples), colored by RCA clusters
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Here, we examined if network principles could be ap-
plied to aid in cell, target, and drug prioritization. Thus,
we constructed network models of the cell types in the
lymph nodes and joints from arthritic mice—henceforth
referred to as multicellular disease models (MCDMs).
Interactions were inferred by connecting whole net-
works of differentially expressed genes in each cell
type with their predicted regulators in all other iden-
tified cell types. These predictions were based on sig-
nificantly enriched interactions in the IPA program
(see the “Methods” section, Additional file 2) [38].
For example, Il1b was predicted as a possible up-
stream regulator of DEGs in granulocytes. We found
that Il1b was differentially expressed in promyeloids.
This led to the identification of a potential interaction
between these two cell types (Fig. 2a–c; Additional
file 2). The predicted interactions were supported by
similar results using another recently described
method (Additional file 2) [40].
In the lymph node, only two cell types, T and B lympho-
cytes, had predicted interactions (Fig. 2a). By contrast, in
the joints, all cell types were connected with each other in a
multi-directional manner, mainly by cytokines and chemo-
kines (Fig. 2b). A possible explanation for more interactions
in the joints could be a larger number of cells than in
lymph nodes (n = 7086 and n = 1333, respectively). How-
ever, we found no significant correlation between the num-
ber of cells of each cell type and the number of outgoing
edges/interactions (Pearson, sick joint r = 0.23, p = 0.66;
healthy joint r = 0.61, p = 0.39). Therefore, a more likely ex-
planation is structural differences between lymph nodes
and the whole joint. Different cell types in lymph nodes
may potentially interact less because they are more local-
ized in dedicated tissue compartments than in joint fluid or
tissue. Visual inspection of the resulting MCDM networks
revealed no obvious key regulatory cell type, such as a
“hub” that had many more interactions than the others, nor
an upstream cell type that regulated the others in a linear
chain (Fig. 2a, b). Similar results were obtained for MCDMs
derived from scRNA-seq from human RA (Additional file
2), as well as when cell types were connected based on an-
other ligand-receptor-based method to infer interactions
(see the “Methods” section, Additional file 2) [40]. This sug-
gested that pathogenic mechanisms were dispersed across
multiple cell types. In support of multicellular pathogenesis,
the differentially expressed genes in most cell types in
scRNA-seq data from both mouse arthritis and human RA
were significantly enriched for genes harboring genetic vari-
ants associated with RA. Those genes were derived from
the DisGeNet database [44], and the mouse analyses based
on the mouse orthologs of those genes (see the “Methods”
section, Additional file 2).
Below, we present data supporting that multicellular
pathogenesis is a general characteristic of complex
diseases and that network analysis in combination with
converging biomedical data can be used to prioritize the
most relevant cell types and genes for diagnostics and
therapeutics.
Analyses of MCDM network properties and enrichment of
RA-associated genetic variants in mouse arthritis
supported that the relatively most important cell types
can be prioritized
Because of the complex, multi-directional interactions in
the MCDMs, we examined if network centrality could
help to prioritize the relatively most important cell types.
A detailed explanation of centrality is given in the
“Methods” section [39, 42]. Briefly, centrality is a meas-
ure of interconnectivity, and our assumption was that
the most central cell types would be relatively most im-
portant for pathogenesis. We used random walk central-
ity as a metric for centrality. For robustness, we also
included subgraph centrality analysis, and a complemen-
tary annotation source to Ingenuity ([43], see the
“Methods” section) which for each case showed similar
results as the random walk centrality (Additional file 4).
As a positive control, we started by analysis of scRNA-
seq from human colorectal tumors [18]. We hypothe-
sized that tumor cells would be more central than sur-
rounding stromal and immune cells. To characterize
surrounding cell types, we used RCA and generated a
reference expression profiling compendium (see the
“Methods” section). We constructed an MCDM and
found that tumor cells were most central, followed by
immune and stromal cells (Additional file 1: Figure S3).
We continued by analyses of centrality in the mouse
MCDM. The relevance of centrality as an indication of
the pathogenic importance of the MCDM cell types was
supported by a significant correlation between centrality
and the degree of enrichment of genes associated with
RA by genetic variants among differentially expressed
genes in each cell type (Pearson r = 0.85, p = 0.03)
(Fig. 2d).
An MCDM of human RA supported multicellular
pathogenesis and centrality to prioritize cell types
In order to test the translational value of centrality, we
constructed an MCDM based on scRNA-seq data from
human synovium from RA patients [23]. We found a
significant correlation between centrality and the degree
of enrichment of genes harboring genetic variants asso-
ciated with RA (Pearson r = 0.57, p = 0.04).
A possible explanation for the lower correlation coeffi-
cient in the human synovium MCDM compared to AIA
could be that the human MCDM lacked a predominant
cell type in RA, namely granulocytes. By contrast, this
cell type category was among the most central and also
most enriched for genes harboring RA-associated
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genetic variants in mouse arthritis. This emphasizes the
importance of performing scRNA-seq analysis on whole
organs to identify pathogenic cell types. However, such
analysis may be complicated by not knowing all organs and
cell types involved in many diseases. In order to obtain an
estimate of cell types and organs involved in human RA,
we analyzed cell-type-specific epigenetic markers that were
enriched for genetic variants associated with RA
(henceforth referred to as GWAS-enriched epigenetic
markers; see the “Methods” section; Additional files 2 and
5). The epigenetic markers were identified in the
Encyclopedia of DNA Elements [56]. These markers in-
cluded both activating and repressive elements identified in
45 primary human cell types. This resulted in the identifica-
tion of 24 cell types and subsets that could be ordered
based on their significance of association (Fig. 3a,
Fig. 2 Multicellular disease models (MCDMs) from a mouse model of AIA. MCDMs were constructed based on scRNA-seq data by connecting
differentially expressed genes in each cell type with predicted upstream regulators in all other cell types. Cell type size corresponds to centrality
score. Numbers indicated by the nodes denote the number of identified cells of specific type (for example in RA joint, we have identified 4258
granulocytes). a An MCDM of lymph nodes from arthritic mice. b An MCDM from arthritic joints. c Multicellular model of a healthy mouse joint
(lymph node model is not shown because there was only one predicted interaction). Gene names of predicted upstream regulators are indicated
on arrows. Treg, T regulatory cells. d Correlation between centrality score of cell types and enrichment of genes harboring genetic variants
identified by GWAS and expert curated repositories among differentially expressed genes (the genes were derived from DisGeNet and the
analysis based on the mouse orthologues of the human genes)
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Fig. 3 Network models of disease-associated cell types. a 24 cell types and subsets that were significantly enriched for GWAS-enriched epigenetic
markers associated with RA. Cell type size corresponds to association −ln (p value). b Network model of cell types associated with human
rheumatoid arthritis (RA). Nodes correspond to cell types, node size corresponds to significance of association (−log10 RA GWAS-epigenetic
marker enrichment p value). Cell types with potential spatial interactions are linked, and cell type position depends on the centrality score as
indicated by the rings in the background. c Bar plot of cell type classes ordered by significance of association with 175 human diseases (Fisher
combined GWAS-enriched epigenetic markers – disease association p value calculated for each cell type class). d Network model of cell types
associated with 175 diseases, based on the same parameters as in b (for details see results)
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Additional file 2). The cell types belonged to two main cat-
egories, immune cells and local stroma or parenchymal
cells.
As expected, immune cell types were most signifi-
cantly associated. The latter category pointed to organs
known, or thought to be involved in RA, namely the
joints, lungs, heart, skin, and liver. Some of these are dif-
ficult to study in human patients, which led us to ask if
centrality could be used to further prioritize cell types
and thereby organs. To explore the centrality of these
categories, we would ideally need the expression profiles
of each cell type to infer molecular interactions and con-
struct a cellular network. Since many of the cell types
are not possible, or difficult to obtain from patients, we
instead used potential spatial interactions as a simple
and binary proxy for molecular interactions. For ex-
ample, a T cell can spatially interact with both bone and
kidney cells, but the latter cannot interact with each
other. These predicted interactions were inferred based
on manual curation (Additional file 2). Using these inter-
actions, we constructed a cellular network model of hu-
man RA (Fig. 3b). In this model, cell type size
corresponded to relative pathogenic importance, as de-
fined by significance of GWAS-enriched epigenetic
markers, and position in the network to centrality. The
model indicated that centrality could potentially be used
to prioritize cell types. Similar to the mouse and human
scRNA-seq MCDMs, the central cell types were mainly
from the immune system, while the peripheral ones were
local parenchymal or stromal cell types from different
tissues (Fig. 3b). Returning to the question if centrality
could help to prioritize between local cell types, osteo-
blasts were actually less central in the model than, for
example, epithelial cells and fibroblasts from the lungs.
While this may seem unexpected given the importance
of joint involvement in RA, this agrees with immune re-
actions in the lungs being proposed to have a primary
pathogenic role [51]. Taken together, these findings sup-
ported the dispersion of pathogenic mechanisms in mul-
tiple immune and local tissue cell types in RA.
A network model of 175 diseases supported multicellular
pathogenesis and centrality to prioritize cell types
Our analyses of AIA and RA led us to ask if multicellu-
lar pathogenesis is a general characteristic of human dis-
eases and if the most important cell types can be
identified in each disease. To address the first question,
about multicellular pathogenesis, we identified cell types
that were significantly associated with 175 diseases that
had been analyzed with GWAS. This was done using
GWAS-enriched epigenetic markers, as described above
for RA (Additional files 2 and 5). We found that the dis-
eases were associated with a median of 20 (0–45) cell
types, which could be potentially ranked in order of
relative importance, based on significance of association
(Fig. 3c). This ranking showed that immune cells were
more significant than local stroma and parenchymal
cells, and was supported by pathway analysis of genes
harboring genetic variant associated with the 175 dis-
eases, which showed that the Th1 and Th2 activation
pathway was most significant (p = 3.22 × 10−34, Add-
itional file 5), followed by other immune-related or gen-
eral pathways. Even after removal of immune diseases,
the Th1 and Th2 activation pathway remained signifi-
cant (p = 3.3 × 10−14; see the “Methods” section). Next,
we examined if centrality analysis could be applied to
prioritize the most important cell types in human dis-
eases. To formally test if there was an association be-
tween cellular centrality and disease risk, we constructed
a single, multicellular network model of the 175 diseases
analyzed with GWAS (henceforth referred to as GWAS
diseases). We used the same construction principles as
for the model of RA (Fig. 3d, see the “Methods” section).
In support of centrality as an explanation for increased
disease risk, we found a significant correlation between
centrality and GWAS-enriched epigenetic markers
(Pearson r = 0.51, p = 3.5 × 10−4).
In summary, the above analyses supported multicellu-
lar pathogenesis as a general disease characteristic, and
the potential to prioritize cell types using GWAS-
enriched epigenetic markers and centrality. Thus, cellu-
lar network models of individual diseases, like the one
for RA, may help to prioritize organs or cell types to
construct scRNA-seq-based MCDMs from human pa-
tients. To facilitate such studies, we have provided net-
work models of each of the 175 diseases, as well as the
underlying data (Additional files 2 and 5).
High cell type interconnectivity implies diagnostic
potential of central and clinically accessible cell types
Both the MCDM of RA and the network model of 175
diseases supported multicellular pathogenesis. While this
complicates therapeutic targeting, the centrality analyses
indicated a potential diagnostic advantage: because of its
interconnectivity with other cell types, any single, central
cell type could serve as a diagnostic sensor of all other
disease-associated cell types in an MCDM. We exam-
ined this possibility in public microarray data from some
central cell types in RA patients, namely CD4+ T cells, B
cells, and CD14+ cells. To prioritize between the large
number of differentially expressed genes between RA
and controls in each cell type, we identified so called
modules, i.e., genes that co-localized on the protein-pro-
tein interaction (PPI) network (Fig. 4a) [2]. We found
that module genes separated patients and controls with
high accuracy (area under the curve, AUCCD4+ T cells =
1.0, p = 5.4 × 10−4, module size = 43; AUCCD14+ = 0.74,
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Fig. 4 (See legend on next page.)
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p = 3.4 × 10−3, module size = 8; AUCB cells = 0.88, p =
4.9 × 10−3, module size = 35).
This led us to examine if a central, functionally rele-
vant and clinically accessible cell type could be used
diagnostically in clinical studies of human patients with
multiple diseases. We focused on expression profiling of
the CD4+ T cell because of its centrality, accessibility in
peripheral blood, and the pathway analyses of the 175
diseases, described above.
Prospective clinical studies of 13 diseases demonstrate
diagnostic potential of CD4+ T cells
Collection of T cell expression profiling data across mul-
tiple diseases is a considerable challenge since it requires
involving specialists from primary, secondary, and ter-
tiary care, laboratory facilities to define inclusion/exclu-
sion criteria, as well as a standardized protocol for T cell
isolation and analysis. To our knowledge, such a study
has not been previously undertaken. Here, we performed
such a study of 13 different diseases to evaluate the diag-
nostic potential of peripheral, total CD4+ T cells, using a
highly standardized protocol. The results were validated
by independent studies. We analyzed autoimmune, aller-
gic, infectious, malignant, endocrine, metabolic, and car-
diovascular diseases (see the “Methods” section), and
age/gender-matched controls.
The diseases were Crohn’s disease, ulcerative colitis,
psoriasis, seasonal allergic rhinitis, asthma, atopic ec-
zema, acute tonsillitis, influenza, breast cancer, chronic
lymphocytic leukemia, type 1 diabetes, obesity, and ath-
erosclerosis. In order to prioritize between differentially
expressed genes in each disease, we constructed modules
(Fig. 4b). For all but one of the 13 diseases, expression
of module genes separated patients from controls with
high accuracy (Fig. 4c, marked with red box, median of
area under the curve, AUC, was 0.98, range 0.82–1; me-
dian p < 2.8 × 10−5, range 8.5 × 10−8 to 7.8 × 10−4; Add-
itional file 2). One disease was separated with less high
accuracy, namely obesity (AUC = 0.82). While obesity is
increasingly recognized as an inflammatory disease [57],
a likely explanation is that it has a greater metabolic
component than the other investigated diseases.
The classifications were not dependent on the classifi-
cation method since similar results were obtained using
20 different methods (Additional file 2). As an example,
the AUC for breast cancer was 1, p = 10−4. An independ-
ent validation study in 24 breast cancer patients and 14
healthy subjects yielded an AUC of 0.82; p = 1.7 × 10−3
(Fig. 4d), which was significantly higher compared to
random genes (p < 3.7 × 10−258).
We also found that the disease module genes sepa-
rated patients with different diagnoses from each other
(Fig. 4c, median AUC 0.98, range 0.27–1; median p <
1.0 × 10−3, range 1.32 × 10−5 to 0.69; Additional file 2).
As an example, the inflammatory bowel diseases ulcera-
tive colitis (UC) and Crohn’s disease (CD), which may be
difficult to separate in clinical practice [58], were classi-
fied with a cross-validated AUC of 0.82 (p < 0.03). Taken
together, our analyses of 13 different diseases support
the diagnostic potential of CD4+ T cells. However, since
expression profiling of T cells is complex in clinical set-
tings, we searched for module intersection genes that
encoded secreted proteins, which could more readily be
measured diagnostically in sera. We identified six such
proteins in UC, CD, and healthy controls (n = 15, 11,
and 20, respectively). All six proteins were differentially
expressed in patients versus controls (non-parametric
Wilcoxon test had 10−8 < p < 4.5 × 10−3, Fig. 4e–j). Using
random elastic net, we ranked those module intersection
genes by their predictive value in discriminating patients
with CD from patients with UC. We proceeded and
aimed for a combination of biomarkers to separate UC
and CD. For this purpose, we applied our previously de-
scribed strategy [59] that avoids any additional param-
eter inferences. Therefore, we expect the results to be
reproducible for a new validation cohort. We normalized
each protein to have unit variance and zero mean in the
(See figure on previous page.)
Fig. 4 Diagnostic potential of CD4+ T cells based on clinical profiling studies of 13 diseases. a Toy model of a disease module. Disease-associated
genes (red) are mapped on proteins (blue) in the human protein-protein interaction network. Disease-associated genes that co-localize form a
module. b Overview of the module-based analyses. First step is the identification of disease modules for each of the 13 diseases profiled in the
prospective microarray study of CD4+ T cells. For each disease module, genes separate patients from healthy controls. For pairwise comparison of
the diseases, genes in the union of two respective modules separate patients with different diseases; for example, genes in influenza and asthma
modules separate patients with influenza from patients suffering from asthma with AUC of 0.99, p = 3.3 × 10−5, as shown in c. c Heatmap
presenting area under the curve (AUC) values of 13 disease classifications based on the module intersections genes, using elastic net. d An
independent validation study of classification accuracy of breast cancer patients (n = 24) and healthy subjects (n = 14) based on previously
preselected biomarkers (genes) measured in CD4+ T cells. Classification was performed with elastic net, preserving same lambda (λ) value as
estimated for the original study. e–j Potential diagnostic classification of IBD patients based on six secreted plasma proteins identified in the
intersection of ulcerative colitis (UC) and Crohn’s disease (CD) modules. These proteins could separate patients from healthy controls (HCs). e
CXCL11; f CCL25; g CXCL1; h CXCL8; i IL1B; j TNF. k Crohn’s disease and ulcerative colitis patients’ classification based on normalized protein
levels of CXCL1 and CXCL8. UC, ulcerative colitis; CD, Crohn disease; HC, healthy controls. Star denotes p value < 0.05. d–k The bars in the boxes
represent median and 25th and 75th percentiles, while whiskers extend to ± 2.7σ (see the “Methods” section)
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healthy controls and tested whether the sum of the nor-
malized levels separated UC and CD. We found that
summing the two proteins with highest individual pre-
dictive values (CXCL1 and CXCL8, Additional file 2)
separated UC and CD with an AUC of 0.81 (double-
sided p = 9.47 × 10−3, Fig. 4k). We emphasize that this
simple approach is likely translatable to new studies, as
long as control samples exist. For all disease pairs of all
13 diseases, we therefore provide respective gene lists
rank-ordered by their predictive value to find highly pre-
dictive combinations of protein biomarkers, similarly to
what we described for UC and CD (Additional file 2).
Pleiotropic mechanisms in T cells are highly enriched for
genetic variants and drug targets
Next, we analyzed the therapeutic potential of T cells.
As described above, this was complicated by the involve-
ment of multiple pathways and drug targets in T cells.
Therefore, we needed a complementary principle to
prioritize disease-associated genes in this cell type. We
hypothesized that, since T cells were associated with
multiple diseases, there could be overlapping, pleio-
tropic, disease mechanisms. If so, those mechanisms
could have a relatively greater pathogenic importance
and therefore be prioritized for therapeutic targeting. If
this could be shown, a general implication could be im-
proved drug prioritization based on analysis of pleio-
tropic mechanisms in central cell types. Indeed, modules
from the 13 diseases partially overlapped on the PPI net-
work, and their union formed what henceforth will be
referred to as a shared interaction neighborhood (SIN;
see the “Methods” section). The pathogenic and thera-
peutic importance of the SIN was supported by highly
significant enrichment of genes harboring genetic vari-
ants associated with the GWAS diseases (n = 261 genes,
odds ratio (OR) = 2.83, p = 1.5 × 10−37), as well as drug
targets (n = 302, OR = 2.92, p = 2 × 10−53).
Identification and validation of drugs targeting the SIN
Because the above analyses supported a general patho-
genic and therapeutic importance of the SIN, we hy-
pothesized that it could be exploited to identify drugs
for that could be effective in many diseases, in which
CD4+ T cells had a central role. We computationally
tested this hypothesis in the 13 diseases analyzed above,
as well as by a therapeutic study of AIA. To find drugs
that optimally targeted SIN genes, we used a recently de-
scribed network-based method [49]. Briefly, we compu-
tationally predicted which of the 1790 drugs in
DrugBank would mainly target genes that were in net-
work proximity with the SIN genes. We identified five
such drugs, which targeted nine of the 13 diseases (Add-
itional file 2). We tested one of these drugs in the mouse
model of AIA. The drug, bezafibrate, is a PPARa agonist
used to treat hyperlipidemia and to prevent cardiovascu-
lar disease [60]. To our knowledge, bezafibrate treatment
has not been described in RA. However, positive effects
of PPARg agonists have been described [61, 62].
In our study of the AIA mice, histological specimens
from arthritic joints that had or had not been treated
with bezafibrate were stained with hematoxylin and
eosin and examined in a blinded manner for an arthritis
score [33]. This ranged from 0–3, where 0 = no signs of
inflammation, 1 = mild inflammation, with proliferation
of the synovial lining layer, and 2 and 3 = different de-
grees of influx of inflammatory cells, as described [33].
We found that bezafibrate treatment significantly de-
creased the arthritis score (p < 0.05; arthritis score in
mock-treated control mice median of 1, range 0.5–2.0;
bezafibrate-treated mice median of 0, range 0.0–0.5;
Fig. 5a, b). Since we have previously shown influx of
neutrophils and lymphocytes in untreated arthritis [63],
and no inflammatory cells were found in the joints fol-
lowing bezafibrate treatment, our study is the first to
show this effect in a mouse model of arthritis. Because
the lymphocyte response was induced by a specific anti-
gen, bovine serum albumin (BSA), we could test if this
response was affected by bezafibrate. Indeed, we found
significantly decreased antigen recall responses in CD4+
T cells in a proliferation assay following bezafibrate
treatment (p = 0.032; number of proliferating cells in
mock-treated control mice median of 1195, range 562–
1599; bezafibrate-treated mice median of 259.5, range
107–809; Fig. 5c).
Discussion
Understanding of pathogenic mechanisms and identifi-
cation of drug targets in complex diseases are daunting
challenges, because of the involvement of thousands of
genes in many different cell types. Ideally, it would be
possible to identify and target a single key regulatory cell
type and mechanism in each disease. Traditionally, such
targets are sought based on empirical or screening ap-
proaches. However, unbiased genome-wide approaches
like GWAS and scRNA-seq studies have indicated the
dispersion of multiple pathogenic mechanisms across
many cell types [13, 64, 65].
This may explain the difficulties in drug discovery and
why many patients do not respond to treatment. Despite
this, systematic characterization and prioritization of dis-
ease-associated cell types and mechanisms for diagnos-
tics and therapeutics remain unresolved challenges. One
obvious approach would be to identify and target the
most significant pathway. In our scRNA-seq study of
AIA, we found that pathways involved in T cell differen-
tiation were most significant. This is consistent with the
current understanding of RA pathogenesis and has re-
sulted in drugs targeting such pathways. However, the
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effects have been variable. A likely explanation was sug-
gested by our systematic analyses of the scRNA-seq data,
which revealed a large number of other pathways and
therapeutic targets in each cell type, as well as limited
overlap between the cell types. This indicates the need
for systems-level approaches to organize and prioritize
cell types and mechanisms for diagnostic and thera-
peutic purposes.
Here, our results support that network-based princi-
ples can be applied for both. We organized scRNA-seq
data from AIA and human RA into MCDMs. Instead of
any unique cell type or mechanism having an obvious
key regulatory role, most cell types in the MCDMs inter-
acted, forming multidirectional networks, in which mul-
tiple cell types potentially contributed to pathogenesis.
Although it is possible that one cell type and mechanism
had a key role, our analysis of genetic and epigenetic
data supported that pathogenic mechanisms were dis-
persed in multiple cell types.
This led us to examine if multicellular pathogenesis
was a general disease characteristic. Indeed, our analyses
of GWAS-enriched epigenetic markers in 175 diseases
showed that a median of 20 cell types was associated
with each disease. However, those analyses were based
on only 45 out of an unknown total number of cell types
in the human body. Therefore, the number of disease-as-
sociated cell types is likely to be much higher. This com-
plexity emphasized the need for strategies to prioritize
the most important disease-associated cell types. Our
subsequent analyses supported that such prioritization is
feasible, based on centrality analyses of our scRNA-seg-
based MCDMs and network models of 175 diseases. We
have provided individual models of all the 175 diseases
(Additional file 5), as well as the underlying data
(Additional file 2), to help prioritization of cell types and
tissues for scRNA-seq-based MCDM construction. Such
prioritization is important because most complex dis-
eases involve multiple organs, some of which may not be
known to be affected in the diseases. For example, the
network model of human RA included 24 cell types and
cell categories, from different organs. One of these was
bronchial epithelium, which is not clinically associated
with RA, but recently proposed to have causal role in
this disease [51].
While dispersion of pathogenic mechanisms in mul-
tiple cell types complicates drug discovery, high inter-
connectivity between cell types may have an unexpected
diagnostic advantage: any central cell type can poten-
tially serve as a sensor of all other disease-associated cell
types. This was supported by our analyses of three differ-
ent immune cells in peripheral blood from RA patients.
To our knowledge, this potential advantage has not been
previously explored. This would be complicated by the
need to perform coordinated clinical studies of multiple
diseases according to standardized protocols. In this
work, we did perform such studies. We first identified T
cells as a suitable diagnostic and therapeutic candidate
cell type both because of its centrality and its clinical ac-
cessibility. The diagnostic potential of T cells was sup-
ported by prospective clinical studies of patients with 13
highly diverse diseases. Expression profiles of this cell
type could be used to separate the different diseases
Fig. 5 Bezafibrate protects against antigen-induced arthritis (AIA). Female mice with mBSA-induced arthritis were intraperitoneally (i.p.) treated
with bezafibrate (n = 4) or mock (AIA control, n = 5). a Arthritis severity was scored based on histopathology day 28 in the two groups (H&E
staining, vertical bars indicate median, differences between groups evaluated using the Mann-Whitney U test, *p < 0.05). b Representative H&E
joint image from the bezafibrate-treated mice. c Antigen recall response of CD4+ helper T cells among spleen and lymph node cells isolated
from mock- (AIA control, n = 5) or bezafibrate-treated (n = 4) mice; vertical bars indicate mean ± SEM, differences between groups evaluated using
the two-sided Mann-Whitney U test *p < 0.05)
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from healthy controls and each other, with high accur-
acy. An independent validation study showed the poten-
tial of T cell profiling to diagnose breast cancer. We also
found that the profiles could be used to infer a limited
number of protein biomarkers for two diseases with par-
tially similar phenotypes, UC and CD. We propose that
the data and methods can be used to identify diagnostic
proteins for any of the 13 diseases, or newly generated
data from other cell types that have been prioritized
based on scRNA-seq-derived MCDMs. For this purpose,
we have included gene lists rank-ordered by the predict-
ive value that can be used to prioritize biomarkers for
further studies. Moreover, based on the example of UC
and CD, we describe a method to identify possible com-
binations of biomarkers from those lists, for better clas-
sification accuracy.
While high interconnectivity between cell types was
diagnostically advantageous, it complicated prioritization
between the many cell types, mechanisms, and drugs.
Here, we focused on T cells because of the centrality and
GWAS analyses. However, this approach was also chal-
lenging due to the involvement of multiple pathways
and predicted drug targets in T cells. We hypothesized
that, since T cells were associated with multiple diseases,
this pleiotropy could be a sign of pathogenic importance.
If so, the same pleiotropic mechanisms could potentially
be exploited for therapeutic targeting of multiple dis-
eases. This was supported by overlap, the SIN, between
modules from the 13 diseases. The pathogenic and
therapeutic importance of the SIN was shown by highly
significant enrichment of genes harboring disease-associ-
ated genetic variants, as well as therapeutic targets.
Using network tools, we computationally predicted five
out of 1790 drugs that optimally targeted the SIN. We
validated one, bezafibrate, in the AIA model. An impli-
cation of this study is that drug prioritization may be
improved by analysis of pleiotropic mechanisms in cen-
tral cell types. This is a finding of considerable potential
importance that, to our knowledge, is novel and merits
further studies.
Limitations of the study include that the bioinformat-
ics analyses of gene interactions, pathways, biomarkers,
and drug targets were based on a manually curated ag-
gregate of multiple data sources, which may be con-
founded by, for example, cell type- or tissue-specific
variations. However, we repeated the analyses using in-
dependent ligand-receptor data with similar results. The
therapeutic implications of our mouse study should be
interpreted with caution, since it was based on a stan-
dardized protocol and inbred mice of the same age and
sex. Indeed, the treatment effects of a related drug were
less pronounced in human patients with RA [61, 62]. A
likely explanation could be the greater complexity and
variability of human RA, as indicated by the pathway
analyses of scRNA-seq data from human RA synovium.
Thus, combinations of drugs targeting multiple pathways
may be required. This highlights the need for future
studies aiming at detailed characterization of dispersion
of pathogenic mechanisms in MCDM cell types, as well
as individual variations. A potential clinical implication
is that, for severe diseases that require costly or risky
medications, scRNA-based MCDMs may provide a
framework to tailor treatments for individual patients,
similar to how we now take high-resolution imaging for
granted [24].
Another important implication is suggested by recent
advances in digital medicine, where different computa-
tional methods, such as artificial intelligence, have been
applied for automated diagnostics of medical images
[66]. Given the molecular complexity of common dis-
eases, successful implementation of digital medicine will
require integration of high-resolution molecular data
with routine data, such as medical images. We and
others have developed network methods for integration
of heterogeneous large-scale data, which may prove use-
ful in this context [2, 29].
Conclusions
Our findings support that MCDMs and network princi-
ples may have the potential to prioritize cell types and
mechanisms for biomarker and drug discovery. All the
presented data and methods have been made available to
facilitate such studies.
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